普祺医药

Core product PG-011 (Pumecitinib) gel has completed Phase 2 clinical trials for adult mild to moderate atopic dermatitis and entered Phase 3 clinical trials. Phase 1b clinical results showed significant efficacy and good safety. The company is exploring its efficacy and safety in adolescent mild to moderate atopic dermatitis. PG-011 gel has completed a Phase 1 clinical trial for nodular prurigo. PG-011 nasal spray for allergic rhinitis is in Phase 2 clinical trials. PG-018 oral administration for membranous nephropathy is in clinical trials. PG-011 gel for epidermolysis bullosa and non-segmental vitiligo is about to start clinical trials, and clinical research for solar dermatitis and radiation dermatitis is in preparation.[2]